Release

Korro Bio Appoints Vineet Agarwal as Chief Financial Officer


CAMBRIDGE, Mass., May 11, 2021—Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Vineet Agarwal as Chief Financial Officer. He joins Korro from J.P. Morgan Chase & Co., where he most recently served as Senior Executive Director in the Healthcare Investment banking group based out of New York and has over 14 years of leadership experience working with innovative biopharma companies.

“Vineet brings an impressive track record of successful strategic transactions in life sciences ranging from high-value equity and debt financings to transformative biopharmaceutical mergers and acquisitions,” said Ram Aiyar, Ph.D., Chief Executive Officer of Korro. “We welcome him to our team and look forward to his contributions in supporting Korro’s growth and mission.”

 “I am excited to join Korro and have the opportunity to work with a team of highly motivated, talented industry veterans in the RNA editing space and to play a role in changing patients’ lives,” said Mr. Agarwal. “Korro’s proprietary technology holds tremendous potential to usher in a new era of RNA editing therapies to treat debilitating diseases. I look forward to leading the finance function and collaborating with the team at Korro to help achieve our mission to rewrite the future for patients.”

Mr. Agarwal began his career with J.P. Morgan in 2007 and has served in numerous leadership roles across different countries. There, he had broad coverage across the life sciences industry, helping companies with mission critical financings including private placements, initial public offerings (IPOs), special purpose acquisition companies (SPACs), primary and secondary equity follow-on offerings (FOs), convertible equity and debt deals. He was also responsible for advising clients on strategic transactions including acquisitions, mergers and licensing deals, and has worked on transformative M&A deals in the biopharma space.

He received his MBA from the Institute of Management Technology, India, and bachelor’s degree in finance from Shri Ram College of Commerce (SRCC), India.

About Korro Bio, Inc.

Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines. The synthetic oligonucleotide platform, OPERATM, is a modular drug discovery engine that combines proprietary data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing. This unique technology enables the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety. As a result, Korro’s portfolio of innovative RNA therapies have the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is located in Cambridge, Mass. For more information, visit korrobio.com.

Media Contact
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com